Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cidara Therapeutics, Inc. (NASDAQ: CDTX).

Full DD Report for CDTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CDTX)

Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary. “We are extre...
Source: Business Wire
Date: December, 03 2018 08:00
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming ...
Source: Business Wire
Date: October, 24 2018 08:00
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be h...
Source: Business Wire
Date: October, 15 2018 08:00
Your Daily Pharma Scoop: Cidara Reports Positive Data, Verastem Beats Arzerra
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other im...
Source: SeekingAlpha
Date: October, 05 2018 13:42
Cidara up 30% premarket on mid-stage rezafungin data
Thinly traded micro cap Cidara Therapeutics (NASDAQ: CDTX ) is up  30%  premarket on light volume on the heels of its announcement of results from the Phase 2 STRIVE study evaluating once-weekly intravenous rezafungin in patients with candidemia and/or invasive candidiasis (yea...
Source: SeekingAlpha
Date: October, 04 2018 08:32
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s ...
Source: Business Wire
Date: October, 04 2018 08:00
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018
WASHINGTON , Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical a...
Source: PR Newswire
Date: October, 03 2018 09:14
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead ant...
Source: Business Wire
Date: September, 27 2018 08:00
Cidara Therapeutics' rezafungin prophylaxis development program nabs QIDP and Fast Track designations
The FDA grants Qualified Infectious Disease Product (QIDP) and Fast Track designations for Cidara Therapeutics' ( CDTX ) prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. More news on: Cidara Therapeutics, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 25 2018 09:42
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics' Rezafungin Prophylaxis Development Program
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food an...
Source: Business Wire
Date: September, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-182.752.552.762.53200,298
2018-12-172.782.753.052.70142,111
2018-12-142.932.782.982.75492,849
2018-12-132.982.983.032.933235,012
2018-12-123.033.003.052.9199,816

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1839,040119,61132.6391Cover
2018-12-1721,35051,93541.1091Short
2018-12-1414,096452,3763.1160Cover
2018-12-132,71610,76725.2252Cover
2018-12-128,69939,57421.9816Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CDTX.


About Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Logo for Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $85,161,719 - 05/11/2018
  • Issue and Outstanding: 20,771,151 - 02/20/2018

 


Recent Filings from (NASDAQ: CDTX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: CDTX)

Daily Technical Chart for (NASDAQ: CDTX)


Stay tuned for daily updates and more on (NASDAQ: CDTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CDTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CDTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CDTX and does not buy, sell, or trade any shares of CDTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/